Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00680342 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment
A Phase 2 study of Chronic Hepatitis C, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
- 5
- Study locations
NCT00680342 is a Phase 2 study of Chronic Hepatitis C that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 154 participants, below the 204-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (25% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT00680342, a Phase 2 study of Chronic Hepatitis C, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
- 5
- Study locations
Study Summary
Silymarin (Legalon), also known as milk thistle, is an alternative medicine commonly found in health food and vitamin stores. People with liver disease sometimes use silymarin because it is thought to have liver protecting effects; however, this benefit has not been proven. The purpose of this research study is to determine the effectiveness of silymarin and assess the safety of different silymarin doses in patients with varying severity of liver disease compared to a placebo (lactose pill). Eligible subjects will be randomized to treatment with placebo or one of two dosages of Legalon® 420 mg or 700 mg administered orally thrice daily. Investigators and subjects will be masked to treatment assignment. The study design includes a screening period during which patients will undergo full medical evaluation to verify protocol eligibility and a treatment period of 24 weeks during which time clinic visits and laboratory studies will be performed every 2-4 weeks to monitor for safety and efficacy of therapy. Subjects will continue to be followed for an additional 12 weeks after the completion of study medication to monitor for adverse events and investigate post-treatment outcomes. Participation in this research study requires the subject to travel to the clinic for at least 10 visits so recruitment will be limited to a geographically restricted area around participating clinical centers.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Silymarin
Study Locations (5)
Pennsylvania
- University of Pennsylvania - Philadelphia
- Thomas Jefferson University - Philadelphia
- University of Pittsburgh - Pittsburgh
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00680342
The ClinicalTrials.gov registry entry for NCT00680342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (25% lower). The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00680342 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00680342 about?
NCT00680342 is a clinical study titled "Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment". Silymarin (Legalon), also known as milk thistle, is an alternative medicine commonly found in health food and vitamin stores. People with liver disease sometimes use silymarin because it is thought to have liver protecting effects; however, this benefit has not been proven. The purpose of this resea...
What is the current status of trial NCT00680342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2008-04. Estimated completion is 2011-01.
What conditions does trial NCT00680342 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT00680342?
The interventions under investigation include: Placebo (OTHER), Silymarin (DRUG).
Who is sponsoring clinical trial NCT00680342?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00680342 being conducted?
This trial has 5 study locations across Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
COMPLETED · Phase 2
-
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
COMPLETED · Phase 2
-
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
COMPLETED · Phase 2
-
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
COMPLETED · Phase 2
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.